Baltimore’s New Federal Tech Hub Designation Positions Region as a Key Player in the Future of Tech and Biotech The designation provides the Greater Baltimore Region with access to a [….]
Who’s Leading Life Science in Baltimore? By Sam Hopkins | October 18, 2023 Success is defined by the ability to zoom in and zoom out at the right time. We [….]
Maryland is buzzing as one of the strongest and most robust life science landscapes in the nation. The state’s proximity to federal agencies keeps Maryland on the forefront of innovation [….]
Talk data to me. Maryland entrepreneur, CEO, investor and advisor, Deborah Hemingway, PhD, Managing Partner, Ecphora Capital, digs into the data-driven team building your company. Measure what matters most to [….]
Johns Hopkins Wilmer Eye Institute Receives $20 Million Donation from T. Boone Pickens Foundation Additional funding from the T. Boone Pickens Foundation will create additional Professorships for young researchers at [….]
A new service in Baltimore will shape the future of laboratory design. The newly-established Showcase Lab highlights how Thermo Fisher Scientific will streamline and personalize lab design and installation for startups and established companies.
Delfi Diagnostics, a Baltimore-based company developing liquid biopsy tests for early cancer detection, will highlight its next-generation liquid biopsy platform at the American Association for Cancer Research’s (AACR) 2023 annual meeting in April.
Eyedea Medical awarded competitive National Science Foundation Phase II Small Business Innovation Research Grant, Baltimore, MD
Serving as a professor at Johns Hopkins for over a decade, Dr. Le recently decided to step out of her comfort zone and start her own company in Baltimore’s Inner Harbor, Gigantest, which provides next-level metabolomics services for scientists and physicians at leading institutions around the world.
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced the publication of results from a Phase 1 study of oral tumor necrosis factor-alpha (TNF-α) inhibitor, MYMD-1® (Isomyosamine), in peer-reviewed journal, Drug Research. The randomized, double-blind, placebo-controlled study, intended to evaluate the safety, tolerability, and pharmacokinetic profile of MYMD-1 in healthy adults, found that single daily doses for 3 days and multiple daily doses for 6 days were safe and well tolerated in healthy subjects. The study used single daily doses of 150 mg, 300 mg, and 450 mg, respectively, and multiple daily doses of 600 mg. There were no new or unexpected safety findings and no clinically relevantor severe adverse events reported.
